Company profile for IntraBio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

IntraBio is a biopharmaceutical company with a late-stage drug pipeline that includes novel treatments for genetic and neurodegenerative diseases. Our clinical programs leverage the expertise of our scientific founders from the University of Oxford and University of Munich, the preeminent experts and pioneers in discovering and developing small molecule drugs that modulate lysosomal function and intracellular calcium signal...
IntraBio is a biopharmaceutical company with a late-stage drug pipeline that includes novel treatments for genetic and neurodegenerative diseases. Our clinical programs leverage the expertise of our scientific founders from the University of Oxford and University of Munich, the preeminent experts and pioneers in discovering and developing small molecule drugs that modulate lysosomal function and intracellular calcium signaling.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
Begbroke Science Park, Begbroke Hill, Woodstock Road, Oxford OX5 1PF
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

ASPEN

ASPEN

Not Confirmed

envelop Contact Supplier

ASPEN

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20260211298909/en/IntraBio-Reports-Further-Detail-on-Positive-Data-from-Levacetylleucine-Pivotal-Trial-for-the-Treatment-of-Ataxia-Telangiectasia

BUSINESSWIRE
11 Feb 2026

https://www.indianpharmapost.com/news/eu-green-light-to-intrabios-aqneursa-for-rare-neurological-disease-niemann-pick-type-c-18983

INDPHARMAPOST
28 Jan 2026

https://www.businesswire.com/news/home/20260121017823/en/IntraBio-Receives-European-Commission-Approval-of-AQNEURSA-for-the-Treatment-of-Niemann-Pick-Type-C-Disease

BUSINESSWIRE
22 Jan 2026

https://www.businesswire.com/news/home/20260121091020/en/IntraBio-Announces-Positive-Pivotal-Trial-Results-of-Levacetylleucine-for-the-Treatment-of-Ataxia-Telangiectasia

BUSINESSWIRE
22 Jan 2026

https://www.businesswire.com/news/home/20250729653942/en/AQNEURSA-levacetylleucine-Recommended-for-EU-Approval-by-the-CHMP-to-Treat-Niemann-Pick-Disease-Type-C

BUSINESSWIRE
29 Jul 2025

https://www.businesswire.com/news/home/20250701009060/en/IntraBio-Inc.-Completes-Recruitment-for-IB1001-A-T-Pivotal-Clinical-Trial

BUSINESSWIRE
01 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty